The potential clinical value of FDG-PET for recurrent renal cell carcinoma

Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose.

Brian M. Gallagher, Joanna S. Fowler, Neal Gutterson et al. · PubMed · 1978 · 560 citations

Life Sciences, Biochemistry, Pharmacokinetics +11

Clinical Use of Fluorodeoxyglucose F 18 Positron Emission Tomography for Detection of Renal Cell Carcinoma

David E. Kang, Richard L. White, James H. Zuger et al. · The Journal of Urology · 2004 · 307 citations

Medicine, Nuclear Medicine, Radiology +17

A SCORING ALGORITHM TO PREDICT SURVIVAL FOR PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A STRATIFICATION TOOL FOR PROSPECTIVE CLINICAL TRIALS

Bradley C. Leibovich, John C. Cheville, Christine M. Lohse et al. · The Journal of Urology · 2005 · 218 citations

Medicine, Biostatistics, Oncology +17

Efficiency of [ 18 F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT

Nicolas Aide, Olivier Cappele, P Bottet et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 205 citations

Medicine, Nuclear Medicine, Radiology +14

F-18 Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Distant Metastases From Renal Cell Carcinoma

Navneet S. Majhail, Jean-Luc Urbain, Justin M. Albani et al. · Journal of Clinical Oncology · 2003 · 204 citations

Medicine, Nuclear Medicine, Oncology +17